ADMA Historical Financial Ratios
| ADMA Stock | USD 17.70 0.93 4.99% |
ADMA Biologics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0694, PTB Ratio of 7.86 or Days Sales Outstanding of 41.63 will help investors to properly organize and evaluate ADMA Biologics financial condition quickly.
ADMA |
About ADMA Financial Ratios Analysis
ADMA BiologicsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ADMA Biologics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ADMA financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ADMA Biologics history.
ADMA Biologics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing ADMA Biologics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ADMA Biologics sales, a figure that is much harder to manipulate than other ADMA Biologics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to ADMA Biologics. There are two different methods for calculating ADMA Biologics invested capital: operating approach and financing approach. Understanding ADMA Biologics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Most ratios from ADMA Biologics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' PTB Ratio is projected to drop based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 41.63, whereas Price To Sales Ratio is forecasted to decline to 3.72.
| 2023 | 2024 (projected) | Dividend Yield | 0.0781 | 0.0694 | Price To Sales Ratio | 3.92 | 3.72 |
ADMA Biologics fundamentals Correlations
Click cells to compare fundamentals
ADMA Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ADMA Biologics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 7.41 | 3.98 | 2.43 | 4.98 | 3.92 | 3.72 | |
| Ptb Ratio | 8.3 | 1.9 | 1.39 | 5.05 | 7.49 | 7.86 | |
| Days Sales Outstanding | 43.15 | 114.44 | 128.86 | 36.73 | 38.76 | 41.63 | |
| Book Value Per Share | 0.48 | 1.02 | 1.01 | 0.77 | 0.6 | 0.9 | |
| Free Cash Flow Yield | (0.37) | (0.68) | (0.64) | (0.0956) | 0.003772 | 0.003961 | |
| Operating Cash Flow Per Share | (1.4) | (1.18) | (0.81) | (0.3) | 0.0393 | 0.0413 | |
| Average Payables | 7.5M | 10.1M | 11.8M | 12.8M | 11.5M | 6.5M | |
| Capex To Depreciation | 1.17 | 3.23 | 2.46 | 1.96 | 0.6 | 0.57 | |
| Pb Ratio | 8.3 | 1.9 | 1.39 | 5.05 | 7.49 | 7.86 | |
| Ev To Sales | 9.38 | 4.97 | 3.07 | 5.42 | 4.27 | 4.06 | |
| Roic | (0.45) | (0.41) | (0.29) | (0.17) | 0.0814 | 0.0855 | |
| Inventory Turnover | 0.74 | 0.75 | 0.64 | 0.73 | 0.98 | 1.36 | |
| Net Income Per Share | (1.45) | (1.05) | (1.02) | (0.61) | (0.43) | (0.13) | |
| Days Of Inventory On Hand | 490.29 | 485.56 | 570.7 | 501.6 | 372.83 | 298.54 | |
| Payables Turnover | 4.31 | 5.53 | 6.42 | 8.98 | 10.81 | 11.35 | |
| Research And Ddevelopement To Revenue | 0.0799 | 0.14 | 0.045 | 0.0235 | 0.0128 | 0.0121 | |
| Capex To Revenue | 0.13 | 0.3 | 0.17 | 0.0903 | 0.0193 | 0.0183 | |
| Cash Per Share | 0.49 | 0.65 | 0.37 | 0.44 | 0.23 | 0.22 | |
| Pocfratio | (2.85) | (1.65) | (1.75) | (12.9) | 115.04 | 120.8 | |
| Interest Coverage | (4.61) | (5.42) | (4.47) | (2.04) | 0.86 | 0.91 | |
| Capex To Operating Cash Flow | (0.0334) | (0.05) | (0.12) | (0.23) | 0.57 | 0.59 | |
| Pfcf Ratio | (2.72) | (1.46) | (1.56) | (10.46) | 265.09 | 278.34 | |
| Days Payables Outstanding | 84.77 | 65.95 | 56.87 | 40.64 | 33.77 | 32.08 | |
| Income Quality | 1.58 | 1.35 | 1.57 | 0.9 | (0.31) | (0.3) | |
| Roe | (2.18) | (0.99) | (0.6) | (0.56) | (0.21) | (0.2) | |
| Ev To Operating Cash Flow | (3.61) | (2.06) | (2.21) | (14.04) | 125.28 | 131.54 | |
| Pe Ratio | (3.81) | (1.92) | (2.33) | (9.01) | (35.85) | (37.64) | |
| Ev To Free Cash Flow | (3.44) | (1.83) | (1.98) | (11.38) | 288.67 | 303.11 | |
| Earnings Yield | (0.26) | (0.52) | (0.43) | (0.11) | (0.0279) | (0.0293) | |
| Intangibles To Total Assets | 0.0526 | 0.0288 | 0.019 | 0.013 | 0.0122 | 0.0116 | |
| Net Debt To E B I T D A | (1.61) | (0.7) | (0.97) | (1.71) | 17.59 | 18.47 | |
| Current Ratio | 6.12 | 7.71 | 6.87 | 6.89 | 5.16 | 3.63 | |
| Tangible Book Value Per Share | 0.36 | 0.96 | 0.97 | 0.75 | 0.59 | 0.85 | |
| Receivables Turnover | 8.46 | 3.19 | 2.83 | 9.94 | 9.42 | 11.42 | |
| Graham Number | 3.37 | 4.84 | 3.71 | 2.73 | 1.31 | 1.24 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.